Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.41 |
| ▸ | IDO1 | P14902 | 5/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14389722 | 0.83 | ALDH1A1 (0.44) | ALDH1A1MAPTGRM7HTR2AHTR2C | |
| SCHEMBL16020167 | 0.81 | ALDH1A1 (0.58) | ALDH1A1MAPTGRM7HTR2AHTR2C | |
| SCHEMBL14698954 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MAPTGRM7HTR2AHTR2C | |
| SCHEMBL364560 | 0.80 | MAPT (0.65) | ALDH1A1MAPTGRM7HTR2AHTR2C | |
| SCHEMBL2639848 | 0.78 | ALDH1A1 (0.58) | ALDH1A1MAPTGRM7HTR2AHTR2C | |
| SCHEMBL20502823 | 0.78 | CYP1A2 (0.42) | ALDH1A1MAPTSCN9AALOX15SMN1; SMN2 | |
| SCHEMBL14399958 | 0.78 | MEN1 (0.58) | ALDH1A1MAPTDYRK3CCNA2CDK2 | |
| SCHEMBL16900306 | 0.78 | ALDH1A1 (0.54) | ALDH1A1MAPTGRM7HTR2AHTR2C | |
| SCHEMBL14697904 | 0.78 | ALDH1A1 (0.57) | ALDH1A1MAPTGRM7HTR2AHTR2C | |
| Benzene SCHEMBL27840008 | 0.77 | ALDH1A1 (0.60) | ALDH1A1MAPTGRM7HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239869-B2 | Sulfonamide compounds as voltage-gated sodium channel modulators | LUPIN LIMITED (IN) | 2019-03-26 | — | — | US | disclosed |
| EP-3344621-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS | Lupin Limited (IN) | 2018-07-11 | — | — | EP | disclosed |
| US-20180186777-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS | LUPIN LIMITED (IN) | 2018-07-05 | — | — | US | disclosed |
| WO-2017037682-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS | LUPIN LIMITED (IN) | 2017-03-09 | — | — | WO | disclosed |
| US-9079902-B2 | Heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079902-B2 | Heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079902-B2 | Heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140256707-A1 | Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256707-A1 | Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2014-09-11 | — | — | US | disclosed |
| EP-2744805-A1 | HETEROARYL SODIUM CHANNEL INHIBITORS | Amgen Inc. (US) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2013025883-A1 | HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013025883-A1 | HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239869-B2 | Sulfonamide compounds as voltage-gated sodium channel modulators | SCN7A, SCN1A, SCN5A | ALDH1A1 1647/4885MAPT 3029/4885GRM7 184/4885 |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | SCN1A, SCN1B, CACNA1B | ALDH1A1 795/4885MAPT 3559/4885GRM7 861/4885 |
| US-20140256707-A1 | Heteroaryl Sodium Channel Inhibitors | SCN1A, SCN5A, SCN1B | ALDH1A1 1377/4885MAPT 3233/4885GRM7 669/4885 |
| US-20180186777-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS | SCN7A, SCN1A, SCN5A | ALDH1A1 1647/4885MAPT 3029/4885GRM7 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.